繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

SNP-810 (SAFETYNADOL)

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC


玩ag电子游戏被黑钱